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patients ; however, it often causes severe complica-
tions. To avoid any unnecessary END, sentinel 
node (SN) biopsy (SNB) for OSCC, which has been 
clinically used in Western countries, will soon be ad-
Introduction
Elective neck dissection (END) is recommend-
ed for N0 oral squamous cell carcinoma (OSCC) 
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Abstract
OBJECTIVE : The aim of this supplemental study of a sentinel node (SN) biopsy (SNB) trial for oral 
squamous cell carcinoma (OSCC) was to assess the effectiveness in identifying micrometastasis and 
determining whether elective neck dissection (END) is necessary.
MATERIALS AND METHODS : Twenty-three patients with pathologically positive SNs were in-
cluded. The sizes of the metastatic lesions in positive SNs (SMSNs) were classified and the rates 
of occult metastasis of non-SNs were compared.
RESULTS : The patients were divided according to the SMSN : <0.2 mm (group A, n=3) ; 0.2 mm 
to <2.0 mm (group B, n=7) ; and ≥2.0 mm (group C, n=13). The rates of occult metastasis in 
groups A, B, and C were 0% (0/3), 14% (1/7) and 23% (3/13), respectively.
CONCLUSION : Rare cancer cell distribution to nodes other than SNs was observed in the patients 
with SN metastatic lesions of at least smaller than 0.2 mm in size, suggesting the possibility of defin-
ing SN micrometastasis in N0 OSCC.
Key words : sentinel node, oral squamous cell carcinoma, micrometastasis.
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opted in Japan to assess the presence of metastasis.　
Although there are various phases of lymph node 
metastasis, from micrometastasis to fully occupied 1), 
there is no concern about the definition of microme-
tastasis in the current TNM system for OSCC. For 
breast cancer, however, it is common to further dif-
ferentiate micrometastasis from macrometastasis 
and treat the conditions differently. However, for 
OSCC, if the sentinel node is pathologically positive, 
neck dissection should be performed. The aim of 
the present study was to assess the effectiveness of 
SNB in identifying micrometastasis and determining 
whether END is necessary for patients with OSCC.　
The present investigation is an original and unique 
attempt to clarify the perspectives to define non-in-
vasive treatment for micrometastasis of OSCC and 
define the novel concept of SNB for OSCC.
Materials
We analyzed the association between treatment 
outcomes and the size of metastatic lesions in the 
SN among patients enrolled in a prospective multi-
center phase II SNB trial titled ‘UMIN000004951 ; 
Evaluation of selective neck dissections based on 
sentinel lymph node navigation in oral cancers’2).　
Patients who were managed at 10 institutions, with 
previously untreated N0 OSCC (n=57) with a clini-
cal tumor stage of ‘‘late-T2’’ (T2 tumor with a diam-
eter of ≥3 cm or any T2 tumor with a tumor depth 
of ≥5 mm) or T3 were included in the present study.
Preoperatively, the SNs were localized using 
conventional lymphoscintigraphy : At 24 h before 
surgery, technetium 99 m (99mTc) phytate (FUJIF-
ILM RI Pharma Co., Ltd. and Nihon Medi-Physics 
Co., Ltd., Japan), which was used as a radiotracer, 
was injected submucosally (74 MBq in 1 mL) at four 
points (one point in each quadrant) around the pri-
mary tumor, and lymphoscintigraphy was performed 
to map the SNs. During surgery, tumor resection 
was performed, followed by the detection of SNs 
with a handheld gamma probe, and selective ND 
with SN basin dissection.　The SNs were immedi-
ately submitted for a frozen section pathological 
analysis, then ranked according to their tracer up-
take level, which was up to 5. All SNs were cut 
into 2-mm blocks, and were subjected to an intraop-
erative frozen section analysis. SNs in which a 
cancer lesion was pathologically detectable were de-
fined as positive SNs, those in which a cancer lesion 
was not pathologically detectable were defined as 
negative SNs. In patients with positive SNs, thera-
peutic ND of levels I, II, III, and IV was performed, 
whereas ipsilateral prophylactic ND of levels I, II, 
and III was performed for patients with negative-
SNs, in a one-stage procedure. Additional sections 
were stained with hematoxylin and eosin (HE) and 
AE1/3 cytokeratin (Signet Laboratories, MA, USA) 
to determine the final postoperative diagnosis. All 
other lymph nodes, including non-radioactive lymph 
nodes, were considered to be non-sentinel nodes 
(NSNs). NSNs were divided longitudinally into two 
specimens, and a single representative cross-section 
was stained with HE to determine the final postop-
erative diagnosis. The details of the clinical meth-
ods and modifications are described in our previous 
paper2).
Methods
Occult metastasis of NSN was defined as the 
presence of cancer cells within NSNs (positive 
NSNs) in the level of therapeutic ND at surgery and 
of post-operative node metastasis (PONM) without 
primary recurrence during the follow-up period.
The sizes of the metastatic lesions in positive 
SNs (SMSNs) based on AE1/3 cytokeratin staining 
were classified into three groups according to the 
AJCC 6th edition for breast cancer3) : isolated tumor 
cells (ITC, group A : single cells or clusters of cells 
of <0.2 mm in diameter) ; micrometastasis (group 
B : 0.2 mm to <2.0 mm in diameter) ; and macro-
metastasis (group C : ≥2 mm in diameter). The 
rates of occult metastasis of NSNs and survival rates 
were compared among the groups. When multiple 
metastatic lesions existed within one lymph node, 
the lesion of the greatest dimension was measured.
Results
The patient characteristics are listed in Table 1.　
Twenty-three patients with metastasis-positive SNs 
were divided into three groups according to the di-
ameter of the metastatic lesions in the SNs.　
Groups A, B and C consisted of 3, 7, and 13 patients, 
respectively. The rates of postoperative node me-
tastasis in groups A, B, and C were 0% (0/3), 14% 
(n=1/7), and 8% (1/13), respectively.　In group C, 
one patient had positive NSNs and developed 
PONM.　Thus, the rates of occult metastasis in 
groups A, B, and C were 0% (0/3), 14% (1/7) and 
23% (3/13), respectively. Although there was no 
significant difference, the 3-year overall survival 
rates of all cases, groups A, B, and C were 83%, 
100%, 57%, 83%, and the 3-year disease-free sur-
vival rates of all cases, groups A, B, and C were 
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74%, 100%, 77%, 74%, respectively.
Discussion
Lymph node metastasis is an important factor 
in the prognosis of OSCC. In the management of 
the neck for early OSCC, the ‘wait and see’ policy is 
not recommended, because both the local control 
rate and survival of patients with lymph node metas-
tasis have been reported to be less than half in com-
parison to patients without lymph node metastasis4,5) 
and it is strongly suggested that END should be rou-
tinely performed6-8). The purpose of SNB for 
OSCC is to distinguish cases where metastasis is 
not detected in the SN and in which END is avoid-
able9). SNB is also reported to be associated with 
significantly higher postoperative mobility and a bet-
ter shoulder function in comparison to END10).　
SNB is useful not only as an accurate diagnostic tool 
for detecting lymph node metastasis, but also as a 
tool for prognostic stratification in various fields of 
cancer11-13). SNB for OSCC is still in the clinical re-
search stage in Japan, but it has been established as 
a standard treatment in Europe14) and the United 
States15), and its consensus has already been reached 
all over the world16).
In the treatment of breast cancer, micrometas-
tasis is considered an important factor for predicting 
the prognosis and selecting surgery17,18). Although 
a patient with either macrometastasis or microme-
Table 1. Patient characteristics.
Characteristic Positive SN Negative SN Total
Number 23 34 57
Age, median (range), years 62 (30-77) 66 (30-85) 64 (30-85)
Male 18 24 42 N/S
Female  5 10 15
Tumor location N/S
 Tongue 22 27 49
 Floor of the mouth  1  3  4
 Alveolar ridge  0  3  3
 Buccal mucosa  0  1  1
T stage N/S
 late T2 20 30 50
 T3  3  4  7
Tumor resection method N/S
 Trans oral 14 26 40
 Pull-through  9  8 17
Reconstruction method N/S
 Pedicle-flap  2  5  7
 Free-flap  5  8 13
Node dissection N/S
 Ipsilateral 18 30 48
 Bilateral  5  4  9
NSN  3  2  5 N/S
PONM  2  1  3 N/S
SN : sentinel node, NSN : non-sentinel node, PONM : post-operative node metastasis
Table 2. Rate of occult metastasis in each group
Group SMSN n Positive NSN PONM Rate of occult metastasis
A 0.2 mm>  3 0 0  0% (0/3)
B =<0.2 mm, 2.0 mm>  7 0 1 14% (1/7)
C =<2.0 mm 13 3 1* 23% (3/13)
Total 23 3 2* 17% (4/23)
SMSN : size of metastatic lesion in positive sentinel node, NSN : non-sentinel node, 
PONM : post-operative node metastasis, *A case had both positive NSN and PONM.
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tastasis is considered pathologically positive for 
lymph node metastasis, ITCs are classified as node-
negative and its prognostic impact was reported to 
be weak19,20). SN selective dissection is sufficient 
for obtaining regional and distant control in patients 
with early-stage breast cancer and micrometastasis 
in the SN21).
The current concept of the sentinel node navi-
gation surgery (SNNS) for OSCC is that therapeutic 
neck dissection should be performed for SN-positive 
cases, and that END is unnecessary for SN-negative 
cases. Although SNB for OSCC has been clinically 
used in Western countries, and a multi-institutional 
study of SNB for head and neck cancer has also been 
undertaken in Japan2,22), the spread of the concept of 
SNB for OSCC is still insufficient. One of the rea-
sons might be the aggressiveness of this concept.　
To define the micrometetastasis for OSCC and dis-
cover the possibility of the low invasive treatment 
for micrometastasis would be necessary. The pres-
ent investigation would be an original and unique at-
tempt to clarify these perspectives.
Occult metastasis did not occur in patients 
whose SMSNs were smaller than 0.2 mm. In other 
words, no cancer cell distribution to nodes other 
than SNs was observed in patients with SN meta-
static lesions at least smaller than 0.2 mm, suggest-
ing the possibility to define the micrometastasis for 
determination whether END is necessary for pa-
tients with OSCC.
A limitation of the present study is its relatively 
small sample size. This analysis was conducted us-
ing the available data of 57 patients in a phase II 
study. A further, larger scale study to establish the 
cutoff value for micrometastasis and to develop an 
individualized, minimally invasive approach is neces-
sary.
Conclusion
No cancer cell distribution to nodes other than 
SNs was observed in patients with SN metastatic le-
sions at least smaller than 0.2 mm, suggesting the 
possibility to determine whether END is necessary 
for patients with OSCC.
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